Major Depressive Disorder Clinical Trials in Staten Island, New York

4 studies are recruiting for major depressive disorder in Staten Island, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

    X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

    Stage
    Phase 3
    Ages
    18 to 74
    Site
    Richmond Behavioral Associates, Staten Island, New York
    Locations
    51 in total
    Run by
    Xenon Pharmaceuticals Inc.

    See if you can join NCT06775379 on ClinicalTrials.gov

  2. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Autobahn Site #104, Staten Island, New York
    Locations
    50 in total
    Run by
    Autobahn Therapeutics, Inc.

    See if you can join NCT06633016 on ClinicalTrials.gov

  3. Study of ALTO-300 in MDD

    The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

    Stage
    Phase 2
    Ages
    18 to 70
    Site
    Site 192, Staten Island, New York
    Locations
    45 in total
    Run by
    Alto Neuroscience

    See if you can join NCT05922878 on ClinicalTrials.gov

  4. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    Stage
    Phase 4
    Ages
    18 to 65
    Site
    Clinical Research Site, Staten Island, New York
    Locations
    40 in total
    Run by
    Axsome Therapeutics, Inc.

    See if you can join NCT06223880 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.